Asymptomatic and mildly symptomatic influenza virus infections by season - Case-ascertained household transmission studies, United States, 2017-2023

Jessica E. Biddle¹, Huong Q. Nguyen², H. Keipp Talbot³, Melissa A. Rolfes¹, Matthew 3 Biggerstaff¹, Sheroi Johnson¹, Carrie Reed¹, Edward A. Belongia², Carlos G. Grijalva³, 4 Alexandra M. Mellis¹ 5 6 ¹ Centers for Disease Control and Prevention, Atlanta, Georgia 7 ² Marshfield Clinic Research Institute, Marshfield, Wisconsin 8 9 ³ Vanderbilt University Medical Center, Nashville, Tennessee 10 11 12 Acknowledgements: The authors would like to thank Alicia Fry, Scott Blackwell, Emma 13 Pedigree Cannon, Holly Morse, Megan Eluhu, Emily Jookar, Christina Khouri, Robert 14 Lvons, Carleigh Frazier, Janika Ravnes, Preston Gibson, Karen Malone, Sarah Davis, 15 Olivia Doak, Judy King, Dayna Wyatt, and the study participants. 16 17 **Financial Support:** These research studies were supported by CDC (grant 18 5U01IP001078 awarded to the Marshfield Clinic Research Institute, grant 19 20 5U01IP001083 awarded to Vanderbilt University Medical Center) and contract 75D30121C11656 jointly funded by the CDC and the US Food and Drug Administration 21 and awarded to Vanderbilt University Medical Center). 22 23 The Vanderbilt Institute for Clinical and Translational Research (VICTR) is funded by 24 the National Center for Advancing Translational Sciences (NCATS) Clinical 25 26 Translational Science Award (CTSA) Program, Award Number 5UL1TR002243-03. The content is solely the responsibility of the authors and does not necessarily represent the 27 official views of the NIH. 28 29 30 **Competing Interest Statement:** EAB receives research support from CSL Segirus unrelated to the current work. HQN receives research support unrelated to this work 31 32 from CSL Segirus, GSK, ModernaTX Inc, and honorarium for participating in a consultancy group for Moderna outside the submitted work. 33 Dr. Grijalva has received consulting fees from Merck, and research support from 34 SyneosHealth, NIH, FDA and AHRQ. 35 36 **Disclaimer:** The findings and conclusions in this report are those of the authors and do 37 not necessarily represent the official position of the US Centers for Disease Control and 38 Prevention. 39 40 41 42 43

44 Abstract

45	Asymptomatic influenza virus infection occurs but may vary by factors such as age,
46	influenza vaccination status, or influenza season. We examined the frequency of
47	influenza virus infection and associated symptoms using data from two case-
48	ascertained household transmission studies (conducted from 2017—2023) with
49	prospective, systematic collection of respiratory specimens and symptoms. From the
50	426 influenza virus infected household contacts that met our inclusion criteria, 8% were
51	asymptomatic, 6% had non-respiratory symptoms, 23% had acute respiratory
52	symptoms, and 62% had influenza-like illness symptoms. Understanding the prevalence
53	of asymptomatic and mildly symptomatic influenza cases is important for implementing
54	effective influenza prevention strategies and enhancing the effectiveness of symptom-
55	based surveillance systems.

56 Introduction

57 Influenza virus infections cause a range of health outcomes, spanning from 58 asymptomatic infection to severe illness including hospitalizations and death. The COVID-19 pandemic has underscored the significance of asymptomatic transmission of 59 60 respiratory pathogens, prompting further research to understand the frequency of asymptomatic infection with influenza virus and its implications on transmission. 61 62 However, studying asymptomatic and mildly symptomatic influenza virus infections is 63 challenging because of the need for prospective and active follow-up [1]. Even with prospective follow-up, estimates of the asymptomatic fraction have been 64 heterogeneous, varying by experimental setting, study design, and case definitions for 65 describing infections as asymptomatic [2-6]. 66

The occurrence of asymptomatic influenza virus infection may also vary by age, 67 vaccination status, and infecting virus type and subtype, but this heterogeneity is not 68 69 well described. Understanding how these factors can influence asymptomatic influenza is crucial for developing effective public health strategies, as they can significantly 70 impact the transmission dynamics and overall burden of influenza in populations. The 71 objective of this analysis was to examine the proportion of asymptomatic influenza virus 72 infections among household contacts and explore the asymptomatic fraction by 73 individual-level factors using recent case-ascertained household studies of influenza 74 that systematically collected daily respiratory specimens and symptoms. 75 Methods 76 Two case-ascertained household transmission studies were conducted in 77 Tennessee and Wisconsin across five influenza seasons from 2017–2023. Index cases 78 with laboratory-confirmed influenza virus infection were enrolled within 7 days of 79 80 symptom onset. At enrollment, all participants self-reported demographics, household characteristics, medical history, symptoms in the week prior to enrollment, and influenza 81 vaccine receipt for the current season. Both index cases and their household contacts 82 were eligible to enroll. Household contacts were defined as those who (1) slept in the 83 same household as the index case for at least half the preceding month. (2) who were 84

present for at least one night in the week before enrollment, and (3) planned to continue
residing in the household during the follow-up period. Enrolled household members had
nasal swabs collected daily, for 5 days (2017-2020 in Wisconsin), 7 days (2017-2020 in
Tennessee), or 10 days (2021-2023 at both sites). During these sampling periods,

89 participants also completed symptom diaries daily. Nasal swabs were tested for

influenza viruses using reverse transcriptase polymerase chain reaction (RT-qPCR). 90 Influenza positive specimens were subtyped according to methods previously 91 described . Participants reported presence or absence of the following signs and 92 symptoms: fever, cough, runny nose, nasal congestion, fatigue, wheezing, shortness of 93 breath, and sore throat on each daily symptom diary. Protocols and procedures were 94 reviewed and approved by the institutional review boards (IRB) at the Marshfield Clinic 95 Research Institute and Vanderbilt University from 2017-2020 and a single IRB at 96 97 Vanderbilt University from 2021-2023.

Analyses were restricted to household contacts who tested positive for influenza. 98 Contacts were excluded if they had less than 3 lab results or daily diaries, or if their first 99 specimen was taken more than 7 days from the index's onset date. Analyses were also 100 restricted to up to 7 days of follow-up. As a sensitivity analysis, we also restricted to 5 101 days of follow-up, which was the minimum duration of symptom surveillance collected at 102 any site during any season. For analyses, we used data from all available daily diaries 103 and implemented 3 definitions to classify the infection: (1) asymptomatic vs 104 105 symptomatic, (2) without acute respiratory illness (ARI) vs with ARI, and (3) without influenza-like illness (ILI) vs with ILI. Being symptomatic was defined as having at least 106 one of the following signs or symptoms: fever, cough, runny nose, nasal congestion, 107 108 fatigue, wheezing, shortness of breath, or sore throat. ARI was defined as having two or more of the following signs or symptoms: fever, cough, runny nose, nasal congestion, or 109 sore throat [8]. ILI was defined as having fever and cough or fever and sore throat. For 110 descriptive purposes, participants were classified into 4 mutually exclusive groups: (1) 111 asymptomatic overall, (2) symptomatic, non-ARI, (3) ARI but not ILI, and (4) ILI. 112

Three multivariable, robust logistic regression models were conducted for each 113 symptom definition to estimate the proportion of influenza positive household contacts 114 who were asymptomatic, did not develop ARI, and did not develop ILI. All regression 115 models accounted for household clustering. Each of the three regression models were 116 further stratified by age group, by season, and by vaccination status. Regression 117 models stratified by age group were adjusted for season and vaccination status. 118 Regression models stratified by season were adjusted for age group and vaccination 119 status. And finally, regression models stratified by vaccination status were adjusted for 120 age group and season. These regression models were used to generate predicted 121 probabilities of the fraction of infected contacts with each symptom presentation, which 122 123 are presented by age, by season, and by vaccination status.

124 **Results**

Four hundred and twenty-six household contacts tested positive for influenza and met our criteria for inclusion. Fifty-four percent of included contacts were from Tennessee, 50% were male, 49% were aged <18 years, 73% were white, non-Hispanic, and 60% were unvaccinated against influenza during the season they were enrolled (Supplemental Table 1). Influenza viruses detected in the infected contacts varied by season (Supplemental Table 1).

From the 426 infected household contacts, 36 (8%) were asymptomatic, 27 (6%) had symptoms but not-ARI, 98 (23%) had ARI but not ILI, and 265 (62%) had ILI during the follow-up period (Figure 1). The proportion of asymptomatic or mildly symptomatic (without ARI) contacts was highest among adult participants (ages ≥18 years) and those who were vaccinated (Figure 1). Additionally, the proportion of asymptomatic or mildly

symptomatic contacts was highest in seasons after the COVID-19 pandemic startedcompared to the pre-pandemic seasons (Figure 1).

We completed three robust multivariable logistic regression models accounting 138 for age, season, and vaccination against each binary case definition for asymptomatic 139 and mildly symptomatic infections. The prevalence of asymptomatic infections across 140 age groups varied: 8% for ages 0–17, 12% for ages 18–49, and 5% for ages \geq 50 years. 141 Similarly, absence of ARI was observed in 16% of contacts for ages 0–17, 17% for ages 142 18–49, and 13% for ages ≥50 years, while absence of ILI occurred in 30% for ages 0– 143 17, 54% for ages 18–49, and 48% for ages \geq 50 years (Table 1). Notably, the 144 prevalence of asymptomatic infections was highest in the 2021-2022 and 2022-2023 145 146 seasons compared to pre-pandemic seasons. Additionally, adjusting for age group and season, 12% of vaccinated contacts and 5% of unvaccinated contacts were 147 asymptomatic. Vaccinated contacts also showed lower percentages of ARI (9% vs 25%) 148 149 and ILI (36% vs. 52%) compared to unvaccinated contacts (Table 1). Trends by age group, season, and vaccination status remained the same when assessments were 150 restricted to the first 5 days of follow-up (Supplemental Table 2). 151

152 **Discussion**

In this study, the proportion of asymptomatic infection among individuals with
laboratory-confirmed influenza was 8% overall. Mildly symptomatic infections,
characterized by the absence of ARI, accounted for 6% of cases, while mildly
symptomatic infections, characterized by the presence of ARI but not ILI, comprised
23% of cases. Consistent with previous studies, we found that asymptomatic influenza
virus infections occur and further show that the asymptomatic fraction, as we estimated

using a household transmission study, varies by season and, possibly, influenzavaccination.

161 Understanding the fraction of individuals with influenza who are asymptomatic or have only mild symptoms has implications for both the prevention of influenza through 162 transmission control and the ability to detect influenza through symptom-based 163 surveillance systems, particularly as these infections may be more common than 164 previously thought, underscoring the significance of our updated evidence. As 165 highlighted by a review by Montgomery et al., if a significant proportion of influenza 166 transmission occurs through individuals with mild or no symptoms, prevention strategies 167 beyond symptom-based case identification, such as vaccination, gain heightened 168 169 importance [1]. In addition, if the fraction of individuals who meet standard case definitions for influenza changes over time or varies age groups, this has implications 170 for continued ability to detect influenza or estimate total illnesses or infections. 171

The present study showed a trend of increased asymptomatic and mildly 172 symptomatic influenza virus infections during the post COVID-19 pandemic seasons. 173 174 Following historically low levels of influenza activity in 2020, which persisted into 2021 [9], there was an increase in the risk of influenza virus infection among household 175 contacts in the 2021-2022 season compared to pre-pandemic seasons [7]. Further 176 177 research is needed to understand the factors that are driving the increase in infections post-pandemic. We hypothesize the increase in infections could be due to increased 178 susceptibility among individuals without recent exposure. We further see that during the 179 180 2021-2022 season, influenza virus infections in this study may have been more mild or 181 were asymptomatic.

Previous studies have examined asymptomatic fraction by age and vaccination 182 status. Consistent with our findings, previous research has shown asymptomatic 183 influenza virus infection among children is less common compared to adults [10]. 184 Findings from the household cohort study out of South Africa further underscores this 185 age-related pattern, showing that the rates of influenza virus infection and symptomatic 186 illnesses were highest in children <5 years and decreased with increasing age [3]. 187 Studies exploring the association of influenza vaccination and asymptomatic fractions 188 within households are lacking. However, one previous study examining the protective 189 effect of influenza vaccination against symptomatic infection in healthcare workers 190 demonstrated that vaccinated health care workers had a higher proportion of 191 asymptomatic influenza virus infection compared to unvaccinated health care workers 192 which is consistent with our present findings [11]. Further research with larger sample 193 sizes should explore the association between vaccination status and progression of 194 195 symptoms.

There are several limitations to our study. First, our study recruited index cases 196 who sought medical care for their illness. Thus, our analysis would not have included 197 household contacts exposed to index cases with milder or asymptomatic presentations 198 that would likely have not sought medical care. Second, serological data, which have 199 been previously used to generate estimates of asymptomatic infections, were not 200 included in this study and therefore we cannot supplement the ascertainment of 201 asymptomatic cases with those data. Additionally, we were unable to stratify data into 202 203 finer-resolved age groups or influenza types/subtypes due to sample size constraints across seasons, limiting the ability to discern more age or influenza-type specific 204

205	patterns of asymptomatic or mildly symptomatic infections. This analysis was restricted
206	to 7 days of active follow-up (median of 9 days of follow up after first illness in the
207	household) and some individuals who were classified as asymptomatic may have
208	developed symptoms later. Finally, we collected data exclusively from households in
209	two US states and therefore our results may not be generalizable to broader
210	populations. Looking forward, future research efforts should consider inclusion of more
211	diverse demographic and geographic settings to ensure a comprehensive
212	understanding of asymptomatic influenza virus infections.
213	These results underscore the value of household transmission studies with close
214	follow-up of exposed household members to better understand the spectrum of
215	symptoms seen in influenza virus infection, including the rate of asymptomatic infection
216	among individuals with influenza.
217	
218	
219	
220	
221	
221	
223	
224	

225 **References**

226	1.	Montgomery, M.P., et al., The role of asymptomatic infections in influenza transmission: what do
227		we really know. The Lancet Infectious Diseases.
228	2.	Tsang, T.K., et al., Reconstructing household transmission dynamics to estimate the
229		infectiousness of asymptomatic influenza virus infections. Proceedings of the National Academy
230		of Sciences, 2023. 120 (33): p. e2304750120.
231	3.	Cohen, C., et al., Asymptomatic transmission and high community burden of seasonal influenza
232		in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population
233		<i>cohort study</i> . The Lancet Global Health, 2021. 9 (6): p. e863-e874.
234	4.	Hayward, A.C., et al., Comparative community burden and severity of seasonal and pandemic
235		influenza: results of the Flu Watch cohort study. Lancet Respir Med, 2014. 2(6): p. 445-54.
236	5.	Leung, N.H., et al., Review Article: The Fraction of Influenza Virus Infections That Are
237		Asymptomatic: A Systematic Review and Meta-analysis. Epidemiology, 2015. 26(6): p. 862-72.
238	6.	Furuya-Kanamori, L., et al., Heterogeneous and Dynamic Prevalence of Asymptomatic Influenza
239		Virus Infections. Emerg Infect Dis, 2016. 22(6): p. 1052-6.
240	7.	Rolfes, M.A., et al., Household Transmission of Influenza A Viruses in 2021-2022. JAMA, 2023.
241		329 (6): p. 482-489.
242	8.	Glossary of Influenza (Flu) Terms. 2024; Available from:
243		https://www.cdc.gov/flu/about/glossary.htm.
244	9.	Olsen, S.J., et al., Changes in Influenza and Other Respiratory Virus Activity During the COVID-19
245		Pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep, 2021. 70(29): p. 1013-
246		1019.
247	10.	Hoy, G., et al., The Spectrum of Influenza in Children. Clin Infect Dis, 2023. 76(3): p. e1012-e1020.
248	11.	Bénet, T., et al., Incidence of Asymptomatic and Symptomatic Influenza Among Healthcare
249		Workers: A Multicenter Prospective Cohort Study. Clinical Infectious Diseases, 2020. 72(9): p.
250		e311-e318.
251		
231		
252		
252		
253		
254		
255		
256		
257		
258		
259		
260		
261		
າດາ		
202		







Symptomatic status was defined using the following symptom definitions (1) Influenza-like Illness (ILI) Symptoms: Fever + (Cough OR Sore Throat), (2) Acute Respiratory Illness (ARI) Symptoms: 2 or more of the following symptoms: Fever, Cough, Runny Nose, Nasal Congestion, Sore Throat, and (3)

Non-ARI Symptoms: At least one of the following symptoms: Fever, Cough, Runny Nose, Nasal

Congestion, Fatigue, Wheezing, Shortness of Breath, Sore Throat. From the 426 included infected household contacts 36 (8%) were completely asymptomatic, 27 (6%) had non-ARI symptoms, 98 (23%)

had ARI symptoms and 265 (62%) had ILI symptoms.

285 Table 1. Characteristics of the cohort & frequencies of asymptomatic infections, United States,

286 2017-2023

	Influenza positive contacts	Asymptomatic influenza positive contacts	Modeled Asymptomatic Infections*	Contacts without ARI	Modeled Infections without ARI*	Contacts without ILI	Modeled Infections without ILI*
	Ν	Ν	% (CI)	Ν	% (CI)	Ν	% (CI)
Age Group					·		
0 – 17 years	208	13	8 (4-14)	26	16 (11-24)	53	30 (23-39)
18 – 49 years	161	19	12 (7-20)	27	17 (11-26)	80	54 (44-63)
50+ years	57	4	5 (2-15)	10	13 (7 – 23)	28	48 (35-61)
Season							
2017 – 2018	45	5	10 (4-23)	7	15 (7-29)	17	38 (24-55)
2018 – 2019	107	5	4 (2- 9)	11	8 (4-16)	34	34 (24-45)
2019 – 2020	152	5	3 (1-9)	8	5 (2-11)	44	34 (26-43)
2021 – 2022	45	7	15 (7-30)	16	36 (21-53)	26	59 (40-75)
2022 – 2023	77	14	17 (9-31)	21	30 (18-46)	40	55 (42-68)
Influenza Vaccination Status							
Vaccinated	169	19	12 (8-18)	37	25 (17-34)	77	52 (42-61)
Unvaccinated	257	17	5 (3-10)	26	9 (6-14)	84	36 (29-44)

287 *A robust logistic regression model accounting for household clustering was conducted to estimate the

proportion of influenza positive household contacts that were asymptomatic, without ARI, and without ILI.

Adjusted marginal estimates and 95% confidence intervals are shown as percentages. Age group was

adjusted for season and vaccination status. Season was adjusted for age group and vaccination status.

291 Vaccination status was adjusted for age group and season.

292

293

294

295

296

297

- 298
- 299
- 300

301

- 302
- 303

Supplemental Table 1. Characteristics of influenza positive contacts by season, United States,2017-2023

Characteristic	Overall , N = 426 ¹	2017-2018 , N = 45 ¹	2018-2019 , N = 107 ¹	2019-2020 , N = 152 ¹	2021-2022 , N = 45 ¹	2022-2023 , N = 77 ¹
State						
TN	231 (54%)	24 (53%)	47 (44%)	46 (30%)	45 (100%)	69 (90%)
WI	195 (46%)	21 (47%)	60 (56%)	106 (70%)	0 (0%)	8 (10%)
Sex						
Female	214 (50%)	26 (58%)	52 (49%)	69 (45%)	29 (64%)	38 (49%)
Male	212 (50%)	19 (42%)	55 (51%)	83 (55%)	16 (36%)	39 (51%)
Race, Ethnicity						
Asian, Non-Hispanic	11 (2.6%)	0 (0%)	3 (2.8%)	8 (5.3%)	0 (0%)	0 (0%)
Black, Non-Hispanic	20 (4.7%)	2 (4.4%)	4 (3.7%)	6 (3.9%)	7 (16%)	1 (1.3%)
Hispanic/Latino	69 (16%)	6 (13%)	12 (11%)	13 (8.6%)	16 (36%)	22 (29%)
Multiple race, Non- Hispanic	9 (2.1%)	0 (0%)	1 (0.9%)	<mark>6 (</mark> 3.9%)	2 (4.4%)	0 (0%)
NH/OPI, Non-Hispanic	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1.3%)
Unknown/Refused	3 (0.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (3.9%)
White, Non-Hispanic	313 (73%)	37 (82%)	87 (81%)	119 (78%)	20 (44%)	50 (65%)
Vaccination Status						
Unvaccinated	257 (60%)	26 (58%)	50 (47%)	100 (66%)	25 (56%)	56 (73%)
Vaccinated	169 (40%)	19 (42%)	57 (53%)	52 (34%)	20 (44%)	21 (27%)
Age Group						
0-17	208 (49%)	16 (36%)	60 (56%)	90 (59%)	15 (33%)	27 (35%)
18-49	161 (38%)	19 (42%)	33 (31%)	50 (33%)	18 (40%)	41 (53%)
50+	57 (13%)	10 (22%)	14 (13%)	12 (7.9%)	12 (27%)	9 (12%)
Flu Type						
A, H1	152 (36%)	8 (18%)	41 (38%)	87 (57%)	2 (4.4%)	14 (18%)
А, НЗ	139 (33%)	24 (53%)	61 (57%)	0 (0%)	29 (64%)	25 (32%)
A, no subtyping	44 (10%)	1 (2.2%)	3 (2.8%)	1 (0.7%)	14 (31%)	25 (32%)
B, no subtyping	82 (19%)	11 (24%)	1 (0.9%)	62 (41%)	0 (0%)	8 (10%)
Unknown	9 (2.1%)	1 (2.2%)	1 (0.9%)	2 (1.3%)	0 (0%)	5 (6.5%)

¹n (%)

Supplemental Table 2. Characteristics of the cohort & frequencies of asymptomatic infections
 with follow-up restricted to 5 days⁺, United States, 2017-2023

	Influenza positive contacts	Asymptomatic influenza positive contacts	Modeled Asymptomatic infections*	Contacts without ARI	Modeled Infections without ARI*	Contacts without ILI	Modeled Infections without ILI*
	Ν	N	% (CI)	N	% (CI)	N	% (CI)
Age Group				•			•
0 – 17 years	204	11	7 (3-12)	24	15 (9-22)	51	29 (22-38)
18 – 49 years	159	19	12 (7-20)	27	17 (11-26)	79	53 (44-62)
50+ years	57	4	5 (2-15)	10	13 (7-23)	28	48 (35-61)
Season							
2017 – 2018	42	3	6 (2-18)	5	11 (5-25)	15	35 (21-52)
2018 – 2019	106	5	4 (2-9)	11	9 (4-17)	34	34 (25-45)
2019 – 2020	150	5	3 (1-9)	8	5 (2-12)	43	34 (25-43)
2021 – 2022	45	7	15 (7-30)	16	36 (22-53)	26	59 (40-75)
2022 – 2023	77	14	17 (9-31)	21	30 (18-46)	40	55 (41-67)
Influenza Vaccination Status							
Vaccinated	167	18	11 (7-17)	36	24 (17-33)	75	51 (41-60)
Unvaccinated	253	16	5 (3-9)	25	9 (6-14)	83	36 (29-44)

309 *A robust logistic regression model accounting for household clustering was conducted to estimate the

310 proportion of influenza positive household contacts that were asymptomatic, without ARI, and without ILI.

Adjusted marginal estimates and 95% confidence intervals are shown as percentages. Age group was

312 adjusted for season and vaccination status. Season was adjusted for age group and vaccination status.

313 Vaccination status was adjusted for age group and season.

⁺Follow-up was restricted to 5 days of follow-up which was the minimum collected per site protocol as

315 sensitivity analyses.

316